{"result_id": "086015", "URL": "https://www.cureus.com/articles/124111-immune-thrombocytopenia-following-booster-dose-of-the-moderna-mrna-1273-vaccine", "timestamp": "2023-04-25 14:53:08 CEST+0200", "meta": {"description": "Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated.\u00a0We present the case of an 81-year-old female patient who became profoundly thrombocytopenic with bleeding manifestations six days after the Moderna mRNA-1273 vaccine administration. Fortunately, she exhibited platelet count recovery after treatment with intravenous immunoglobulins and steroid therapy. Furthermore, we show that the inherent risk of COVID-19 infection leading to thrombocytopenia significantly outweighs the vaccine\u2019s risk.", "lang": "en", "keywords": "", "favicon": "https://assets.cureus.com/packs/media/images/favicon-6b3259c58f4356da2cc885357cfda20b.png", "canonical": "https://www.cureus.com/articles/124111-immune-thrombocytopenia-following-booster-dose-of-the-moderna-mrna-1273-vaccine", "encoding": "utf-8"}, "image": null, "domain": "www.cureus.com", "title": "Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine", "cleaned_text": "On May 25, 2018, the GDPR (General Data Protection Regulation) went into effect and changed how organizations deal with personal data of customers located in the EU. Though GDPR was built to protect Europeans, it will affect organizations around the world doing business in the EU. Because of this we are asking our users located in the EU to opt in to the data we collect in order to bring a better web experience. Opt-In", "opengraph": {"title": "Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine", "type": "article", "image": "https://public.cureus.com/fallback/new_default_article_image_2.png", "description": "Vaccine-mediated immune thrombocytopenia, although previously reported, is considered exceedingly rare. The probability of the incidence of profound thrombocytopenia following the COVID-19 mRNA-based vaccine has been less elucidated.\u00a0We present the case of an 81-year-old female patient who became profoundly thrombocytopenic with bleeding manifestations six days after the Moderna mRNA-1273 vaccine administration. Fortunately, she exhibited platelet count recovery after treatment with intravenous immunoglobulins and steroid therapy. Furthermore, we show that the inherent risk of COVID-19 infection leading to thrombocytopenia significantly outweighs the vaccine\u2019s risk."}, "tags": [], "tweets": [], "movies": [], "links": ["/users/gdpr_opt_in"], "authors": ["Daniel Cooper", "Shane A. Reeves", "Shane Reeves", "Katherine A. Breetz", "Samra Haroon Lodhi", "Taha Ahmed", "Daniel P. Cooper"], "publish_date": null}